{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:13:02Z","timestamp":1785031982062,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,15]]},"DOI":"10.7759\/cureus.82293","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:50:42Z","timestamp":1744725042000},"source":"Crossref","is-referenced-by-count":4,"title":["The Role of Antipsychotic Medications on Metabolic and Hematological Parameters"],"prefix":"10.7759","author":[{"given":"Abdalla M","family":"Jarari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagannadha R","family":"Peela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zakoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Hawda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Abd El Rasoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh Srinivas T","family":"Peela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeja","family":"Addagarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basheer","family":"Madompoyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01317.x","article-title":"The metabolic syndrome and schizophrenia","volume":"119","author":"Meyer JM","year":"2009","unstructured":"Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009, 119:4-14. 10.1111\/j.1600-0447.2008.01317.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7358.243","article-title":"Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study","volume":"325","author":"Koro CE","year":"2002","unstructured":"Koro CE, Fedder DO, L'Italien GJ, et al.. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002, 325:243. 10.1136\/bmj.325.7358.243","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson DC","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000, 157:975-81.","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing DA","year":"2002","unstructured":"Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002, 63:856-65.","journal-title":"J Clin Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak MJ","year":"2002","unstructured":"Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002, 159:561-6. 10.1176\/appi.ajp.159.4.561","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson DC","year":"2005","unstructured":"Henderson DC, Nguyen DD, Copeland PM. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005, 66:1116-21.","journal-title":"J Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(00)02066-3","article-title":"Association of venous thromboembolism and clozapine","volume":"355","author":"H\u00e4gg S","year":"2000","unstructured":"H\u00e4gg S, Spigset O, S\u00f6derstr\u00f6m TG. Association of venous thromboembolism and clozapine. Lancet. 2000, 355:1155-6.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.12.003","article-title":"Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: a systematic review and meta-analysis","volume":"92","author":"Limveeraprajak N","year":"2025","unstructured":"Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2025, 92:4-11. 10.1016\/j.genhosppsych.2024.12.003","journal-title":"Gen Hosp Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert M","year":"2009","unstructured":"De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009, 8:15-22.","journal-title":"World Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll CU","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, et al.. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017, 16:163-80. 10.1002\/wps.20420","journal-title":"World Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.143182","article-title":"Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment","volume":"6","author":"Wani RA","year":"2015","unstructured":"Wani RA, Dar MA, Margoob MA, Rather YH, Haq I, Shah MS. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract. 2015, 6:17-22. 10.4103\/0976-3147.143182","journal-title":"J Neurosci Rural Pract"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14m09300","article-title":"Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort","volume":"76","author":"Goldstein BI","year":"2015","unstructured":"Goldstein BI, Schaffer A, Wang S, Blanco C. Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. J Clin Psychiatry. 2015, 76:163-9.","journal-title":"J Clin Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.09.009","article-title":"Essential elements in depression and anxiety. Part II","volume":"67","author":"M\u0142yniec K","year":"2015","unstructured":"M\u0142yniec K, Gawe\u0142 M, Doboszewska U, Starowicz G, Pytka K, Davies CL, Budziszewska B. Essential elements in depression and anxiety. Part II. Pharmacol Rep. 2015, 67:187-94. 10.1016\/j.pharep.2014.09.009","journal-title":"Pharmacol Rep"},{"key":"ref14","article-title":"Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotic medication","volume":"22","author":"Kozumplik O","year":"2010","unstructured":"Kozumplik O, Uzun S, Jakovljevi\u0107 M. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotic medication. Psychiatr Danub. 2010, 22:69-74.","journal-title":"Psychiatr Danub"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller BJ","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011, 70:663-71. 10.1016\/j.biopsych.2011.04.013","journal-title":"Biol Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295x.104.4.667","article-title":"Schizophrenia: a neural diathesis-stress model","volume":"104","author":"Walker EF","year":"1997","unstructured":"Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997, 104:667-85. 10.1037\/0033-295x.104.4.667","journal-title":"Psychol Rev"},{"key":"ref17","article-title":"Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery J","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen RC. Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Psychopharmacol. 2004, 65:1491-8.","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19:1-93. 10.2165\/00023210-200519001-00001","journal-title":"CNS Drugs"},{"key":"ref19","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze WK","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003, 28:519-26.","journal-title":"Neuropsychopharmacology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht KL","year":"2007","unstructured":"Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007, 32:289-97. 10.1038\/sj.npp.1301209","journal-title":"Neuropsychopharmacology"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.3390\/nu17060959","article-title":"Hematological correlations as predictors of disease manifestations in psychiatric inpatients","volume":"17","author":"Doma\u0144ski M","year":"2025","unstructured":"Doma\u0144ski M, Doma\u0144ska A, Lachowicz-Wi\u015bniewska S, \u017bukiewicz-Sobczak W. Hematological correlations as predictors of disease manifestations in psychiatric inpatients. Nutrients. 2025, 17:959.","journal-title":"Nutrients"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert M","year":"2011","unstructured":"De Hert M, Correll CU, Bobes J, et al.. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011, 10:52-77. 10.1002\/j.2051-5545.2011.tb00014.x","journal-title":"World Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2011.12.005","article-title":"Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression","volume":"36","author":"Leonard B","year":"2012","unstructured":"Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012, 36:764-85. 10.1016\/j.neubiorev.2011.12.005","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353862-the-role-of-antipsychotic-medications-on-metabolic-and-hematological-parameters","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:50:44Z","timestamp":1744725044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353862-the-role-of-antipsychotic-medications-on-metabolic-and-hematological-parameters"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.82293","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}